| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-065 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 第六届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 次触发转股价格向下修正条款，届时公司董事会将再次召开会议决定是否行使"蓝帆 转债"转股价格向下修正权利。 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 具体内容详见刊登于公司指定的信息披露媒体《中国证券报》、《上海证券报》、《证 券时报》、《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）上的《关于向下修正 "蓝帆转债"转股价格的公告》。 三、备查文件 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第二十七次会议于2025 年8月11日以电子邮件的方式发出通知，于2025年8月14日在公司第一会议室以现场及 通讯表决相结合的方式召开。本次会议应参加会议董事8人，实际参加会议董事7人；刘 文静女士、钟舒乔先生、赵敏女士以现场的方 ...

融券方面，当日融券卖出0.00万股，净买入0.16万股。 来源：金融界 8月13日，沪深两融数据显示，蓝帆医疗获融资买入额0.23亿元，居两市第1807位，当日融资偿还额0.16 亿元，净买入738.26万元。 最近三个交易日，11日-13日，蓝帆医疗分别获融资买入0.15亿元、0.29亿元、0.23亿元。 ...

Group 1 - The stock price of Bluestar Medical closed at 6.33 yuan on August 13, 2025, down 0.63% from the previous trading day, with a trading volume of 115 million yuan and a total market capitalization of 6.375 billion yuan [1] - Bluestar Medical's main business includes medical devices and emergency rescue products, with its emergency rescue division having a leading global production capacity for first aid kits, covering various scenarios such as home use, vehicle use, and public places, and has received multiple international certifications [1] - The company is a key drafting unit for the national standard revision of "Household Disaster Emergency Kits," which will be implemented on November 1, 2025, raising performance and quality requirements for emergency kits [1] Group 2 - On August 13, 2025, the main funds for Bluestar Medical experienced a net outflow of 5.6814 million yuan, with a cumulative net outflow of 15.5755 million yuan over the past five trading days [2]

Core Insights - The coronary artery stent market in China is projected to reach approximately $7.0 billion by 2024, with a year-on-year growth of 6.4% [5][6]. Market Overview - In 2023, 8.368 million patients were hospitalized for coronary heart disease, with 1.901 million undergoing PCI (Percutaneous Coronary Intervention), where stent placement accounted for 81.2% of these procedures [3][6]. Product Structure - Drug-eluting stents (DES) dominate the market, expected to account for 69% of market revenue in 2024. The increasing prevalence of hypertension and diabetes due to aging populations and lifestyle changes is driving demand for DES [7][6]. Development Trends - **Material Innovation**: New alloy materials such as platinum-chromium and nickel-titanium are increasingly used due to their superior mechanical properties and biocompatibility. Biodegradable materials like polylactic acid and polycaprolactone are also being adopted to mitigate long-term foreign body reaction risks [11]. - **Functional Innovation**: Improvements in drug carriers for drug-eluting stents enhance drug release efficiency, reducing the risk of late thrombosis. Smart stents integrating sensors can monitor physiological parameters in real-time and adjust drug release accordingly [11].

8月12日，沪深两融数据显示，蓝帆医疗获融资买入额0.29亿元，居两市第1336位，当日融资偿还额0.29 亿元，净买入30.97万元。 最近三个交易日，8日-12日，蓝帆医疗分别获融资买入0.11亿元、0.15亿元、0.29亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 ...

齐鲁晚报·齐鲁壹点 连宁燕 姜本政表示，未来吉威医疗将持续加大创新力度，未来在创新通道等政策的全力支持下，有信心让广大 人民群众尽快用到更新、更好的产品，并实现自身经营业绩和品牌实力的可持续增长。 近日，威海市政府新闻办举行"产业链上的山东好品牌"威海首场系列新闻发布会，主题是威海医药与医 疗器械产业链，山东吉威医疗制品有限公司总经理姜本政围绕产业链创新发展和品牌打造等主题分享交 流。 姜本政介绍，吉威医疗抢抓医械行业的黄金发展机遇，坚定不移走创新驱动高质量发展道路，在母公司 蓝帆医疗（002382）的支持下，累计投入约20亿元用于研发创新，陆续推出多款兼具独特性、有效性的 创新产品面向市场，至今已新获批产品注册证12张。这其中包括2024年获批的具有独家专利的冲击波血 管内碎石系统，国内独家高出血风险病人适应症的超短双抗药物涂层支架BioFreedom、通过国家药监局 创新通道获批的国内首款冠脉药物球囊柏腾BA9 DCB等重磅创新产品，该款产品的小血管适应症和支 架内再狭窄适应症的临床结果分别在美国TCT大会及欧洲EuroPCR会议上公布，2025年EuroPCR上支架 内再狭窄适应症临床结果的文章获得最佳 ...

| 89 | 山东潍坊润丰化工股份有限公司 | | --- | --- | | 90 | 山东华建铝业集团有限公司 | | 91 | 山东联盟化工集团有限公司 | | 92 | 山东潍坊百货集团股份有限公司 | | 93 | 即发集团有限公司 | | 04 | 泰山体育产业集团有限公司 | | 95 | 山东海鼎农牧有限公司 | | 96 | 山东巨量引擎信息技术有限公司 | | 97 | 临工重机股份有限公司 | | 98 | 滨州中裕食品有限公司 | | da | 山东海王医药集团有限公司 | | 100 | 中创物流股份有限公司 | | 101 | 青岛汉河集团股份有限公司 | | 102 | 山东益通安装有限公司 | | 103 | 鲁南制药集团股份有限公司 | | 104 | 中启胶建集团有限公司 | | 105 | 山东步长制药股份有限公司 | | 106 | 山东龙大美食股份有限公司 | | 107 | 玫德集团有限公司 | | 108 | 青岛新协航国际物流有限公司 | | 100 | 山东海力化工股份有限公司 | | 110 | 潍坊恒信建设集团有限公司 | | 111 | 史丹利农业集团股 ...

Core Viewpoint - The disposable glove industry is approaching a turning point, with the price of nitrile gloves expected to recover in the second half of 2025 [2][17]. Group 1: Market Dynamics - Demand has surged due to the pandemic, but is now returning to a normalized growth pattern [6][10]. - Supply-side adjustments have led to the effective clearance of small and medium-sized capacities, alleviating supply redundancy [11][13]. - The supply-demand relationship is returning to balance, with nitrile glove prices expected to rise monthly in 2024 [13][15]. Group 2: Competitive Landscape - Chinese companies have rapidly caught up with Malaysian firms in terms of production capacity, maintaining high utilization rates [21][23]. - The production cost of nitrile gloves in China is significantly lower than that in Malaysia, enhancing competitiveness [24]. - Chinese companies have accumulated more cash reserves in recent years, improving their risk resilience and strategic flexibility [26][28]. Group 3: Regulatory Impact - Chinese companies have largely exited the U.S. nitrile glove market due to tariff-related disruptions, which have now been effectively cleared [29][32]. - The U.S. has implemented new tariffs on Chinese nitrile gloves, significantly impacting export dynamics [30][32]. Group 4: Price Trends and Profitability - The downward price pressure on nitrile gloves is limited, with potential for significant profit elasticity as prices rise [34]. - Raw material prices have decreased, which may mitigate profit disturbances related to declining glove prices [37][42]. Group 5: Future Opportunities - Some Chinese companies are exploring overseas manufacturing to continue exporting to the U.S., which could provide incremental revenue [36]. - The anticipated recovery in nitrile glove prices in the second half of 2025 presents an opportunity for profit growth [39].

Core Viewpoint - The article provides a comprehensive overview of the Chinese biomedical materials industry, highlighting key listed companies, their business segments, revenue projections, and strategic planning for future growth. Group 1: Overview of Listed Companies - The A-share listed companies in the biomedical materials sector include Guocera Materials, Weigao Orthopedics, Haohai Biological Technology, Lepu Medical, Lanfang Medical, and Xinmai Medical [1] - The industry is characterized by a diverse range of companies focusing on various segments such as biocomposite materials, biopolymers, and biometals [2][3] Group 2: Revenue Projections - For 2024, key revenue figures for selected companies include: - Guocera Materials: 40.47 billion CNY from dental ceramics and biomedical materials [4] - Weigao Orthopedics: 14.51 billion CNY from orthopedic implants [10] - Lepu Medical: 61.03 billion CNY from cardiovascular materials [5] - The overall revenue for the biomedical materials sector is projected to grow, driven by increasing demand for advanced medical solutions [11] Group 3: Business Layout and Performance - Companies like Aojing Medical, Weigao Orthopedics, and Dabo Medical derive nearly 100% of their revenue from biomedical materials, indicating a focused business strategy [9] - The production and sales rates for biomedical materials are generally below 100%, with companies like Aojing Medical and Weigao Orthopedics showing lower production efficiency [11] Group 4: Strategic Planning and Innovation - Leading companies are focusing on technological innovation, market expansion, and integration of the supply chain to maintain competitive advantages [13] - Companies such as Guocera Materials and Weigao Orthopedics are investing in R&D and international market penetration to enhance their product offerings and market share [14][15]

证券日报网讯蓝帆医疗（002382）8月5日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东人数为76827户。 ...